Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Rank in Stocks #107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Share Price
$41.14
Last synced: 2026-09-21
Market Cap
$182.76B
Change (1 day)
-7.78%
Change (1 year)
-32.24%
Country
DK
Trade Novo Nordisk A/S (NOVO-B)

Category

Revenue for Novo Nordisk A/S (NOVO-B)
Revenue in Jun 2026 TTM: $52.30B
According to Novo Nordisk A/S latest financial reports the company's current revenue (TTM) is $52.30B. In 2024 the company made a revenue of $40.52B an increase over the revenue in the year 2023 that was $34.39B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Novo Nordisk A/S from 2000 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $52.30B 12.04%
2025 $46.68B 15.22%
2024 $40.52B 17.82%
2023 $34.39B 35.02%
2022 $25.47B 18.29%
2021 $21.53B 3.33%
2020 $20.84B 13.79%
2019 $18.31B 6.63%
2018 $17.17B -4.59%
2017 $18.00B 13.46%
2016 $15.86B 0.88%
2015 $15.73B 8.89%
2014 $14.44B -6.28%
2013 $15.41B 11.69%
2012 $13.80B 19.42%
2011 $11.55B 6.01%
2010 $10.90B 10.52%
2009 $9.86B 15.53%
2008 $8.54B 3.65%
2007 $8.24B 20.44%
2006 $6.84B 28.15%
2005 $5.34B -0.14%
2004 $5.34B 18.51%
2003 $4.51B 27.01%
2002 $3.55B 25.45%
2001 $2.83B 9.05%
2000 $2.60B 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$79.67B 52.31%
US
$97.93B 87.23%
US
$64.39B 23.10%
US
$77.52B 48.21%
CH
$66.40B 26.95%
US